Last edition
News about
BD has launched Research Cloud 7.0 globally, introducing the AI-driven Horizon Panel Maker to automate panel design, streamline workflows and enhance data quality in immunology and cancer research.
China Approves Trelegy Ellipta for Uncontrolled Asthma
China has approved Trelegy Ellipta for adults with uncontrolled asthma, extending its use beyond COPD and making it the only single-inhaler triple therapy for both conditions in the country.
Akums Secures EU GMP Approval for Two Haridwar Facilities
The approvals follow successful EU-GMP audits of Akums’ two Haridwar manufacturing facilities, with the drug regulator renewing certification for plant I and granting fresh approval to plant II after assessing operations, quality systems, documentation and compliance with EU GMP standards.
SK bioscience, MSD and Hilleman Advance Ebola Vaccine with CEPI Funding
he collaboration will receive up to USD 30 million in CEPI funding to support development of MSD’s Zaire ebolavirus vaccine, with a focus on improving manufacturing efficiency, enhancing thermostability and expanding affordable vaccine access in low- and middle-income countries.
Syngene International reported a muted financial performance for the third quarter of FY26, with consolidated revenue declining three percent year on year to INR nine hundred thirty two crore, compared with INR nine hundred sixty two crore in the same quarter last year. Profit after tax, before exceptional items, stood at INR seventy three crore.
Janux Therapeutics has entered into a global collaboration and exclusive licensing agreement with Bristol Myers Squibb to develop a novel cancer therapy for solid tumours. The partnership is valued at up to USD eight hundred fifty million, including upfront payments and development, regulatory, and commercial milestones.
Dr Reddy's Q3 FY26 Net Profit Falls Fourteen Percent Despite Revenue Growth
Dr Reddy’s Laboratories reported consolidated revenue of INR eight thousand seven hundred twenty seven crore in the third quarter of financial year twenty six, registering year on year growth.
Galderma to Spotlight Injectable Aesthetics Innovation at IMCAS 2026 with Ten Scientific Posters
Galderma, the pure-play dermatology category leader with operations in nearly 90 countries, will present ten scientific posters highlighting the latest advances across its injectable aesthetics portfolio at the International Master Course on Aging Science (IMCAS) 2026 World Congress, to be held in Paris, France, from January 29 to 31, 2026.
FDA Grants Orphan Drug Status to BlueRock's OpCT-001
The ODD supports the clinical development of OpCT-001, the first iPSC-derived investigational cell therapy to enter human trials for Retinitis Pigmentosa (RP), a common inherited retinal disease marked by progressive loss of photoreceptor cells.
Zydus Launches World's First Nivolumab Biosimilar 'Tishtha' in India
Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of the immunotherapy drug nivolumab, in India, aimed at expanding access to advanced cancer care by offering the treatment at nearly one-fourth the cost of the reference product for patients with multiple cancer types.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy